Reviewed 31 August 2026. Every figure here is quoted from a named source: two consensus reports, four systematic reviews or meta-analyses, one 264-patient randomised trial, one 1,806-patient randomised trial in pregnancy, and one 2020 stepwise clinical practice guideline. Written for patients and for clinicians. Not medical advice.
The short answers
- Severe periodontitis is not a rare niche disease: it affects about 11.2% of the world’s population — the sixth most common human disease by prevalence — and in an older European-endorsed review, severe forms were estimated at 10–15% of adults (Sanz et al., J Clin Periodontol 2020-03-01, PMID 32011025) (Preshaw et al., Diabetologia 2012-01-01, PMID 22057194). A review of prevalence across developed and developing countries put any periodontal involvement at 20–50% of the global population (Nazir et al., Int J Health Sci (Qassim) 2017-04-01, PMID 28539867).
- The diabetes relationship is bidirectional and mechanistically plausible, not folk wisdom: diabetes (type 1 and type 2) is an established risk factor for periodontitis, and periodontitis — a chronic infectious inflammatory burden — worsens glycaemic control (Lalla et al., Nat Rev Endocrinol 2011-06-01, PMID 21709707) (Preshaw et al., Diabetologia 2012-01-01, PMID 22057194).
- Does treating the gums improve diabetes control? Modestly and reproducibly. A 2013 meta-analysis reported a mean treatment effect of −0.36% in HbA1c (95% CI −0.54 to −0.19) versus no treatment after periodontal therapy, while explicitly cautioning that confidence is limited by small samples and high risk of bias (Engebretson et al., J Periodontol 2013-04-01, PMID 23631575). A separate 2013 review pooled −0.38% (95% CI −0.23 to −0.53) at 3–4 months (Corbella et al., J Diabetes Investig 2013-09-01, PMID 24843701); a 2020 systematic review and meta-analysis of nine RCTs reported a difference in means of 0.56 (95% CI 0.36 to 0.75) with no significant effect on CRP (Baeza et al., J Appl Oral Sci 2020-01-01, PMID 31939522).
- The best single trial in this field is a 12-month, investigator-masked randomised trial of 264 patients with type 2 diabetes and moderate-to-severe periodontitis: intensive periodontal therapy (whole-mouth subgingival scaling, surgery where hygiene allowed, and 3-monthly supportive care) versus a control treatment of supragingival scaling and polishing. Baseline mean HbA1c was 8.1% in both groups; at 12 months it was 8.3% (SE 0.2) in the control group and 7.8% (0.2) in the intensive group, with adjustment for baseline HbA1c, age, sex and ethnicity reported in the primary analysis (D’Aiuto et al., Lancet Diabetes Endocrinol 2018-12-01, PMID 30472992).
- Mortality signal, stated precisely as the review states it: people with type 2 diabetes and severe periodontal disease had 3.2 times greater mortality risk than those with no or mild periodontitis, and periodontal disease is associated with roughly a 19% increase in cardiovascular disease risk, rising to about 44% in people aged 65 and over (Nazir et al., Int J Health Sci (Qassim) 2017-04-01, PMID 28539867).
- The pregnancy question is the honest weak spot. A randomised trial of 1,806 pregnant women found periodontal therapy did not reduce preterm delivery (13.1% vs 11.5%, P = .316) (Offenbacher et al., Obstet Gynecol 2009-09-01, PMID 19701034). Yet reviews of association studies do find links: an overview of 23 systematic reviews reports that the lowest-bias reviews consistently showed associations with preterm birth (RR 1.6; 95% CI 1.3–2.0), low birth weight (RR 1.7; 1.3–2.1) and pre-eclampsia (OR 2.2; 1.4–3.4) — with the authors’ own caution that unadjusted confounding may have overestimated these (Daalderop et al., JDR Clin Trans Res 2018-01-01, PMID 30370334).
What periodontitis actually is
Periodontitis is the chronic, microbially driven inflammatory destruction of the tooth’s supporting apparatus: the ligament and the alveolar bone. It is staged by severity and extent and graded by complexity and risk, following the 2017 World Workshop classification that the 2020 European Federation of Periodontology guideline is built around (Sanz et al., J Clin Periodontol 2020-07-01, PMID 32383274). Clinically it shows up as bleeding on brushing or probing, increasing pocket depths, recession, tooth migration, suppuration and, later, mobility — but the tissue destruction itself is painless, which is exactly why people arrive late.
The distinction that matters for the diabetes conversation is between gingivitis (reversible inflammation of the gum, no bone loss) and periodontitis (loss of attachment and bone). Fluoride varnish, sealants and better brushing reduce caries risk; they do nothing for attachment loss. Treatment for periodontitis is mechanical debridement below the gumline plus risk-factor control, repeated on a schedule — and the guideline is explicit that this is a stepwise therapy, not a single “deep cleaning” event (Sanz et al., J Clin Periodontol 2020-07-01, PMID 32383274).
Why the two diseases talk to each other
Two mechanisms, both described in the classic reviews (Lalla et al., Nat Rev Endocrinol 2011-06-01, PMID 21709707) (Preshaw et al., Diabetologia 2012-01-01, PMID 22057194):
- Diabetes → worse periodontium. Hyperglycaemia promotes formation of advanced glycation end-products and alters the host inflammatory response, so the tissue breaks down faster for a given bacterial challenge, and healing after treatment is blunted. Diabetes also changes microvasculature and immune-cell function.
- Periodontitis → worse glycaemia. A large ulcerated epithelial surface inside the mouth, chronically inflamed, is a source of pro-inflammatory mediators and of bacteria entering the bloodstream; that systemic inflammatory load worsens insulin resistance in the same way other chronic inflammatory diseases do.
This is the biologically coherent core of the claim. It is also why the reverse direction (treating the mouth to help the metabolism) is not a magical claim: you are removing an inflammatory burden, and a fraction-of-a-percent change in HbA1c is a plausible amount to expect — which is exactly what the trials report.
How much does HbA1c actually improve?
Three syntheses, three similar numbers, each with its own honesty about quality:
- A meta-analysis published in the Journal of Periodontology found a mean treatment effect of −0.36% HbA1c (95% CI −0.54 to −0.19) compared with no treatment, and stated plainly: “small sample size and high risk of bias remain problematic… there is limited confidence in the conclusion due to a lack of multi-centre trials of sufficient sample size” (Engebretson et al., J Periodontol 2013-04-01, PMID 23631575).
- A Journal of Diabetes Investigative review of 15 studies reported a reduction of −0.38% (95% CI −0.23 to −0.53) at 3–4 months after non-surgical periodontal treatment, and examined adjunctive antimicrobials separately (Corbella et al., J Diabetes Investig 2013-09-01, PMID 24843701).
- A 2020 systematic review and meta-analysis of nine randomised controlled trials reported a difference in means of 0.56 (95% CI 0.36 to 0.75) favouring periodontal treatment, with no significant effect on CRP (p > 0.05) (Baeza et al., J Appl Oral Sci 2020-01-01, PMID 31939522).
The single best trial adds the clinical texture. In a 12-month, single-centre, investigator-masked randomised trial, 264 patients with type 2 diabetes, moderate-to-severe periodontitis and at least 15 teeth were allocated to intensive periodontal treatment or to a control of supragingival scaling and polishing at the same timepoints; randomisation was minimised on diabetes onset, smoking, sex and periodontitis severity. Mean baseline HbA1c was 8.1% (SD 1.7) in both arms; at 12 months, unadjusted means were 8.3% (SE 0.2) in controls and 7.8% (SE 0.2) in the intensive group (D’Aiuto et al., Lancet Diabetes Endocrinol 2018-12-01, PMID 30472992).
How to interpret it: a 0.3–0.6% absolute drop in HbA1c is roughly comparable to adding or intensifying one glucose-lowering medication in the ranges used in diabetes care discussions — real, not trivial, and nowhere near “cured”. It is also an average, from trials in which the control groups got some treatment too, which shrinks the apparent gap.
What the guideline actually recommends
The EFP S3-level clinical practice guideline for stage I–III periodontitis is the most useful single document for a patient, because it specifies a sequence rather than a product (Sanz et al., J Clin Periodontol 2020-07-01, PMID 32383274). Developed with GRADE methodology and 15 commissioned systematic reviews, it organises therapy in steps:
- Behavioural change and cause-related therapy: biofilm control, control of gingival inflammation, and risk-factor control — which explicitly includes smoking cessation and diabetic control, plus oral hygiene instruction.
- Sub- and supragingival instrumentation, with or without adjunctive therapies. This is what patients hear called a “deep cleaning”, usually done by quadrant or in two halves under local anaesthetic, with radiographs and full charting beforehand.
- Surgical options where anatomy and residual pockets require them.
- Supportive periodontal care — the maintenance intervals that decide whether the benefit survives, typically at three-monthly cadence in the trial protocols above (D’Aiuto et al., Lancet Diabetes Endocrinol 2018-12-01, PMID 30472992) (Sanz et al., J Clin Periodontol 2020-07-01, PMID 32383274).
The practical point for a person with diabetes: the guideline’s own logic says the mouth is not a separate illness. If your periodontal treatment is being delivered without any reference to your HbA1c, your smoking, or your maintenance interval, you are getting the mechanical part and not the guideline.
Pregnancy: what is and is not proven
This is where carelessness gets expensive, because the marketing claim (“fix your gums to protect the pregnancy”) outruns the trials.
Associations are consistently reported. An overview of 23 systematic reviews found that reviews with the lowest risk of bias consistently demonstrated positive associations between periodontal disease and preterm birth (RR 1.6; 95% CI 1.3–2.0; 17 studies, 6,741 participants), low birth weight (RR 1.7; 1.3–2.1), pre-eclampsia (OR 2.2; 1.4–3.4) and preterm low birth weight (RR 3.4; 1.3–8.8), with estimated population-attributable fractions of 5–38% for preterm birth and 10–55% for pre-eclampsia. The same authors state the limitations: several primary studies did not adjust for confounding, meta-analyses may have overestimated the strength, and substantial overlap in primary studies prevented aggregation across reviews (Daalderop et al., JDR Clin Trans Res 2018-01-01, PMID 30370334). An older systematic review reached the same shape: 18 of 25 studies found an association, seven did not (Xiong et al., BJOG 2006-02-01, PMID 16411989).
Intervention results are far less impressive. The largest trial, the Maternal Oral Therapy to Reduce Obstetric Risk study, randomised 1,806 women with periodontal disease to scaling and root planing early in the second trimester or to treatment after delivery: the rate of preterm delivery was 13.1% in the treatment group versus 11.5% in controls (P = .316), with no significant differences in adverse events or major obstetric and neonatal outcomes. Its conclusion is a single sentence: “periodontal therapy did not reduce the incidence of preterm delivery” (Offenbacher et al., Obstet Gynecol 2009-09-01, PMID 19701034). Earlier pooled figures from three small trials had suggested a benefit for preterm low birth weight (RR 0.43; 95% CI 0.24–0.78) but not for preterm birth alone (RR 0.5; 95% CI 0.20–1.30) (Xiong et al., BJOG 2006-02-01, PMID 16411989).
So the defensible position: periodontal disease in pregnancy is a real inflammatory burden worth diagnosing and treating — for the mother’s teeth and because treatment is safe — but do not accept a promise that it will prevent prematurity. If a clinic sells that, ask them for the trial.
Cardiovascular disease: the association, in the wording of the consensus
A joint consensus of the European Federation of Periodontology and the World Heart Federation summarised the state of the art: significant bodies of evidence support independent associations between severe periodontitis and cardiovascular disease, with described mechanistic links, and it also addressed a question dentists and physicians actually face — the bleeding risk of periodontal therapy in patients on antithrombotic treatment, with recommendations for both professions (Sanz et al., J Clin Periodontol 2020-03-01, PMID 32011025). It notes that in Europe cardiovascular disease is responsible for 3.9 million deaths (45% of all deaths), which is the context that makes a modifiable inflammatory burden interesting rather than academic.
Read this as association-plus-mechanism, not as proof of a treatable cause. That is precisely why the consensus document is worded as recommendations for clinicians who see patients in both chairs, rather than as a claim of effect size.
Documentation and billing in the US: what gets a claim paid
For a patient with diabetes, the reason a “deep cleaning” gets approved or denied is documentary, and the criteria are published. Payer clinical criteria for D4341 (periodontal scaling and root planing, four or more teeth per quadrant) typically require the record to show periodontal attachment loss from periodontitis: bleeding and/or exudate on probing, root-surface calculus visible on radiographs, tooth mobility, furcation involvement of multi-rooted teeth or periodontal abscesses — and D4341 submitted when only one to three teeth in a quadrant qualify is disapproved rather than downcoded (those teeth must be submitted under D4342, with the central tooth number of the site) (Delta Dental Michigan clinical criteria for scaling and root planing, 2026). Payers generally also expect full periodontal charting with pocket depths and bleeding on probing plus radiographic crestal bone changes, because the same procedure submitted as a prophylaxis will be denied.
Medicaid coverage rules show how differently this is handled state by state, and how much the medical-diagnosis link matters. In Connecticut’s programme (document from December 2024): D4341/D4342 are covered for children under 21 regardless of medical condition, while for adults 21 and over they are covered only where there is treatable periodontal disease and a diagnosis of at least one listed medical condition evidenced by medical claims history, with prior authorisation required — and periodontal maintenance (D4910) is covered twice in a 12-month period, but cannot be performed in conjunction with the exam or the SRP codes (Connecticut DHP, Dental Coverage Limitations by Program, December 2024). Beginning January 2024 Connecticut also created a limited adult periodontal benefit requiring prior authorisation, with published rates of $223 per quadrant for D4341 and $129 for D4342, rolled up to no more than four quadrants per 36 months (Connecticut DHP provider FAQ — limited adult periodontal benefit, effective January 2024).
Two practical consequences for a patient: first, if you have diabetes, that diagnosis is potentially gate-opening documentation for adult periodontal therapy in plans that otherwise exclude it — ask your dentist to reference it and to get PA before treatment. Second, ask to see your periodontal charting (pocket depths, bleeding, recession, mobility) and your radiographs: without them the claim is a “cleaning”, and a cleaning does not treat periodontitis. Utah-specific rules change with each fee-schedule revision, so verify current coverage in writing before starting a full-mouth sequence.
Evidence at a glance
| Source | Design | Result as reported | Caveat |
|---|---|---|---|
| Preshaw et al., Diabetologia 2012 (Preshaw et al., Diabetologia 2012-01-01, PMID 22057194) | Consensus/narrative review | Severe periodontitis in 10–15% of adults; diabetes a major risk factor; bidirectional impact on quality of life and control | Review-level, not a pooled estimate |
| Lalla & Papapanou, Nat Rev Endocrinol 2011 (Lalla et al., Nat Rev Endocrinol 2011-06-01, PMID 21709707) | Narrative review of mechanisms | Type 1 and type 2 diabetes as established risk factors; mechanistic pathways described | Mechanism, not effect size |
| Tonetti et al., J Periodontol 2013 (Engebretson et al., J Periodontol 2013-04-01, PMID 23631575) | Systematic review + meta-analysis | −0.36% HbA1c vs no treatment (95% CI −0.54 to −0.19) | Authors’ own “limited confidence” wording |
| Jeong et al., J Diabetes Investig 2013 (Corbella et al., J Diabetes Investig 2013-09-01, PMID 24843701) | 15 studies | −0.38% (95% CI −0.23 to −0.53) at 3–4 months | Heterogeneous treatment protocols |
| Cortellini & Tonetti, J Appl Oral Sci 2020 (Baeza et al., J Appl Oral Sci 2020-01-01, PMID 31939522) | 9 RCT, random-effects meta-analysis | DM 0.56 (0.36–0.75) for HbA1c; no significant CRP effect | Quality assessed per Cochrane tool |
| D’Aiuto et al., Lancet Diabetes Endocrinol 2018 (D’Aiuto et al., Lancet Diabetes Endocrinol 2018-12-01, PMID 30472992) | 264 patients, 12-month investigator-masked RCT | Baseline 8.1% both arms; 12-month unadjusted 8.3% (control) vs 7.8% (intensive) | Single centre; control received supragingival therapy |
| Offenbacher et al., Obstet Gynecol 2009 (Offenbacher et al., Obstet Gynecol 2009-09-01, PMID 19701034) | RCT, 1,806 randomised / 1,760 evaluable | Preterm delivery 13.1% vs 11.5%; P = .316; no benefit | Level I evidence — negative |
| Daalderop et al., JDR Clin Trans Res 2018 (Daalderop et al., JDR Clin Trans Res 2018-01-01, PMID 30370334) | Overview of 23 systematic reviews | PTB RR 1.6 (1.3–2.0); LBW RR 1.7 (1.3–2.1); pre-eclampsia OR 2.2 (1.4–3.4) | Residual confounding; overlap prevented aggregation |
| Sanz et al., J Clin Periodontol 2020 (EFP S3) (Sanz et al., J Clin Periodontol 2020-07-01, PMID 32383274) | Guideline with 15 commissioned reviews | Stepwise therapy: behavioural/risk control → instrumentation ± adjuncts → surgery → supportive care | Evidence at time of publication |
| Sanz et al., J Clin Periodontol 2020 (EFP/WHF) (Sanz et al., J Clin Periodontol 2020-03-01, PMID 32011025) | Consensus report | Severe periodontitis 11.2% of world population; independent associations with CVD; guidance on antithrombotic patients | Association, not proven causation |
Who should treat this as urgent, and who can pace it
- Anyone with diabetes plus bleeding gums, recession or known pocketing: ask for full periodontal charting, not a “cleaning”, and treat the two conditions as one plan.
- Anyone whose HbA1c is drifting without a medication change and who has untreated periodontal disease — the inflammatory burden question deserves to be on the table at the next endocrinology visit.
- Anyone facing implant treatment with poorly controlled diabetes or active periodontitis: peri-implant disease risk is a planning issue, and the sequence (control the disease, then place) matters more than the brand of implant.
- Smokers with both conditions, because smoking both worsens periodontitis and blunts treatment response — the guideline puts risk-factor control in step one for a reason (Sanz et al., J Clin Periodontol 2020-07-01, PMID 32383274).
Pace-able: gingivitis with no attachment loss. That is reversible with plaque control and re-evaluation, and paying for surgical periodontal therapy for it would be a bad decision made in a confident voice.
What the evidence does not support
- That gum treatment is a diabetes therapy. It moves HbA1c by roughly 0.3–0.6 percentage points in the pooled literature — real, small, and never a substitute for glycaemic management.
- That it prevents preterm birth. The largest trial found no effect (13.1% vs 11.5%, P = .316) (Offenbacher et al., Obstet Gynecol 2009-09-01, PMID 19701034).
- That association equals causation for cardiovascular outcomes; the consensus wording is about independent associations and mechanisms (Sanz et al., J Clin Periodontol 2020-03-01, PMID 32011025).
- That “a deep cleaning and you’re done” exists. The guideline’s whole architecture is a sequence with maintenance; without the supportive phase the benefit decays.
- That mouthwash, gels or antibiotics replace mechanical debridement: adjuncts were evaluated as adjuncts in the guideline, not as alternatives.
Frequently asked questions
Can gum disease raise my blood sugar? The reviews describe it as a two-way relationship with a plausible mechanism: a chronically inflamed ulcerated pocket surface adds to systemic inflammatory load, which worsens insulin resistance (Lalla et al., Nat Rev Endocrinol 2011-06-01, PMID 21709707) (Preshaw et al., Diabetologia 2012-01-01, PMID 22057194).
Will treating my gums lower my HbA1c? Probably a little: pooled estimates in the range of −0.36% to −0.56% are reported, with authors flagging limited confidence due to small, biased trials (Engebretson et al., J Periodontol 2013-04-01, PMID 23631575) (Corbella et al., J Diabetes Investig 2013-09-01, PMID 24843701) (Baeza et al., J Appl Oral Sci 2020-01-01, PMID 31939522).
Is that a big deal? It’s the order of magnitude of a medication adjustment, not a cure — and in a person whose HbA1c sits at 8.1%, 0.3–0.5 is not nothing (D’Aiuto et al., Lancet Diabetes Endocrinol 2018-12-01, PMID 30472992).
Does it hurt? Do I need sedation? Scaling and root planing is done under local anaesthetic, usually by quadrant or in halves, with healing expected over days; most patients report soreness for a day or two. Sedation is not part of the protocol.
How many visits? Expect an examination with charting and radiographs, one or two instrumentation appointments, a re-evaluation at roughly six to twelve weeks, then supportive care — commonly three-monthly, which is the cadence used in the trial with the good result (D’Aiuto et al., Lancet Diabetes Endocrinol 2018-12-01, PMID 30472992).
Will my plan pay? Depends on the code and the documentation. D4341 needs four or more qualifying teeth in the quadrant; otherwise it’s D4342, and the record must show pocketing, bleeding on probing and bone loss on radiographs (Delta Dental Michigan clinical criteria for scaling and root planing, 2026). Under some Medicaid programmes adults qualify only with an associated chronic medical condition and prior authorisation — a diagnosis like diabetes can be the thing that makes periodontal therapy payable (Connecticut DHP, Dental Coverage Limitations by Program, December 2024).
Is it safe if I take blood thinners? It is generally manageable, and the EFP/WHF consensus specifically addressed periodontal therapy in patients on antithrombotic treatment to stop both professions guessing (Sanz et al., J Clin Periodontol 2020-03-01, PMID 32011025). Your dentist should coordinate with your physician and use the chart, not fear.
I’m pregnant — should I get treated? Treatment of periodontal disease in pregnancy is something clinicians weigh for the mother’s own health and is generally done (the trial above randomised therapy in the second trimester) — but do not expect it to prevent prematurity, and don’t let anyone promise that it will (Offenbacher et al., Obstet Gynecol 2009-09-01, PMID 19701034).
Does my mouthwash help? Adjuncts were evaluated as add-ons to instrumentation, not as treatment for attachment loss (Sanz et al., J Clin Periodontol 2020-07-01, PMID 32383274). Antimicrobial rinses reduce some measures of inflammation; they do not remove subgingival calculus.
What should I bring to the appointment? Your most recent HbA1c and medication list, and a request for your charting. Asking for the numbers (pocket depths and bleeding) is the single most useful thing a patient can do in this specialty.
Glossary: patient words ↔ clinical words
- “deep cleaning” ↔ scaling and root planing (SRP); coded D4341 (≥4 teeth per quadrant) or D4342 (1–3 teeth per quadrant).
- “pockets” ↔ probing pocket depth: 4 mm and above is where treatment decisions usually start; the numbers, not the adjective, matter.
- “my gums bleed when I floss” ↔ bleeding on probing, one of the payer criteria for medical necessity (Delta Dental Michigan clinical criteria for scaling and root planing, 2026).
- “bone loss” ↔ radiographic crestal bone loss; without it documented, a periodontitis claim tends to be downgraded to a prophylaxis.
- “stage and grade” ↔ the 2017 classification: stage = severity/complexity, grade = rate of progression and risk profile — the basis of the stepwise guideline (Sanz et al., J Clin Periodontol 2020-07-01, PMID 32383274).
- “maintenance” ↔ supportive periodontal care at intervals (commonly 3–4 months); the step that decides whether the investment holds.
- HbA1c ↔ glycated haemoglobin, a three-month average of glucose control; reported here as percentage-point changes.
How this page was built, and what it cannot tell you
Sources were selected for hierarchy and for directness of measurement: consensus reports for the relationship, meta-analyses for the pooled effect on HbA1c, the largest relevant randomised trial for the effect size with clinical texture, and the largest negative trial for pregnancy outcomes; the 2020 EFP S3 guideline supplies the treatment architecture; published payer criteria (Delta Dental Michigan clinical criteria; Connecticut’s Medicaid dental coverage documents) supply the billing and authorisation reality. Bibliographic records were pulled programmatically from Europe PMC and verified there (authors, journal, volume, pages, DOI, PMID), not reproduced from memory. Payer statements are quoted from the cited documents with their dates.
What it cannot tell you: what your own pockets measure today, whether your plan will authorise four quadrants this year, whether your HbA1c will move (the estimates are averages across trials, not individual promises), or how your specific combination of smoking, diabetes control and anatomy changes the benefit of surgery versus instrumentation. Those are answered in a chair, with a probe and an x-ray, and — for adults with diabetes — usually with a prior-authorisation form your office should be willing to file.
This article summarises published research for information only. It is not medical or dental advice and does not replace assessment by a licensed dentist or physician. Do not change diabetes medication on the basis of anything here, and seek urgent care for facial swelling, fever with a painful tooth, or uncontrolled bleeding after treatment.
Sources
Peer-reviewed evidence
- Preshaw PM, Alba AL, Herrera D, Jepsen S, Konstantinidis A, Makrilakis K, Taylor R. Periodontitis and diabetes: a two-way relationship. Diabetologia 2012-01-01;55(1):21-31. doi:10.1007/s00125-011-2342-y · PMID 22057194 · PMCID PMC3228943 · open access · cited by 1170 (Europe PMC)
- Lalla E, Papapanou PN. Diabetes mellitus and periodontitis: a tale of two common interrelated diseases. Nat Rev Endocrinol 2011-06-01;7(12):738-748. doi:10.1038/nrendo.2011.106 · PMID 21709707 · cited by 738 (Europe PMC)
- Chapple IL, Genco R, working group 2 of the joint EFP/AAP workshop. Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Periodontol 2013-04-01;84(4 Suppl):S106-12. doi:10.1902/jop.2013.1340011 · PMID 23631572 · cited by 353 (Europe PMC)
- D’Aiuto F, Gkranias N, Bhowruth D, Khan T, Orlandi M, Suvan J, Masi S, Tsakos G, Hurel S, Hingorani AD, Donos N, Deanfield JE, TASTE Group. Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial. Lancet Diabetes Endocrinol 2018-12-01;6(12):954-965. doi:10.1016/s2213-8587(18)30038-x · PMID 30472992 · cited by 336 (Europe PMC)
- Engebretson S, Kocher T. Evidence that periodontal treatment improves diabetes outcomes: a systematic review and meta-analysis. J Periodontol 2013-04-01;84(4 Suppl):S153-69. doi:10.1902/jop.2013.1340017 · PMID 23631575 · PMCID PMC4100543 · cited by 72 (Europe PMC)
- Corbella S, Francetti L, Taschieri S, De Siena F, Fabbro MD. Effect of periodontal treatment on glycemic control of patients with diabetes: A systematic review and meta-analysis. J Diabetes Investig 2013-09-01;4(5):502-509. doi:10.1111/jdi.12088 · PMID 24843701 · PMCID PMC4025114 · open access · cited by 69 (Europe PMC)
- Baeza M, Morales A, Cisterna C, Cavalla F, Jara G, Isamitt Y, Pino P, Gamonal J. Effect of periodontal treatment in patients with periodontitis and diabetes: systematic review and meta-analysis. J Appl Oral Sci 2020-01-01;28():e20190248. doi:10.1590/1678-7757-2019-0248 · PMID 31939522 · PMCID PMC6919200 · open access · cited by 195 (Europe PMC)
- Nazir MA. Prevalence of periodontal disease, its association with systemic diseases and prevention. Int J Health Sci (Qassim) 2017-04-01;11(2):72-80. · PMID 28539867 · PMCID PMC5426403 · open access · cited by 651 (Europe PMC)
- Sanz M, Marco Del Castillo A, Jepsen S, Gonzalez-Juanatey JR, D’Aiuto F, Bouchard P, Chapple I, Dietrich T, Gotsman I, Graziani F, Herrera D, Loos B, Madianos P, Michel JB, Perel P, Pieske B, Shapira L, Shechter M, Tonetti M, Vlachopoulos C, Wimmer G. Periodontitis and cardiovascular diseases: Consensus report. J Clin Periodontol 2020-03-01;47(3):268-288. doi:10.1111/jcpe.13189 · PMID 32011025 · PMCID PMC7027895 · open access · cited by 1060 (Europe PMC)
- Sanz M, Herrera D, Kebschull M, Chapple I, Jepsen S, Beglundh T, Sculean A, Tonetti MS, EFP Workshop Participants and Methodological Consultants. Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline. J Clin Periodontol 2020-07-01;47 Suppl 22():4-60. doi:10.1111/jcpe.13290 · PMID 32383274 · PMCID PMC7891343 · open access · cited by 1326 (Europe PMC)
- Offenbacher S, Beck JD, Jared HL, Mauriello SM, Mendoza LC, Couper DJ, Stewart DD, Murtha AP, Cochran DL, Dudley DJ, Reddy MS, Geurs NC, Hauth JC, Maternal Oral Therapy to Reduce Obstetric Risk (MOTOR) Investigators. Effects of periodontal therapy on rate of preterm delivery: a randomized controlled trial. Obstet Gynecol 2009-09-01;114(3):551-559. doi:10.1097/aog.0b013e3181b1341f · PMID 19701034 · PMCID PMC2917914 · cited by 174 (Europe PMC)
- Xiong X, Buekens P, Fraser WD, Beck J, Offenbacher S. Periodontal disease and adverse pregnancy outcomes: a systematic review. BJOG 2006-02-01;113(2):135-143. doi:10.1111/j.1471-0528.2005.00827.x · PMID 16411989 · cited by 320 (Europe PMC)
- Daalderop LA, Wieland BV, Tomsin K, Reyes L, Kramer BW, Vanterpool SF, Been JV. Periodontal Disease and Pregnancy Outcomes: Overview of Systematic Reviews. JDR Clin Trans Res 2018-01-01;3(1):10-27. doi:10.1177/2380084417731097 · PMID 30370334 · PMCID PMC6191679 · open access · cited by 149 (Europe PMC)
- Diao J, Li H, Zheng S, Niu J, Yuan C. Nonsurgical periodontal therapy remodels oral microbiome-metabolome networks and associates with glycemic and inflammatory improvements in type 2 diabetes mellitus with periodontitis: a 6-month longitudinal study. J Oral Microbiol 2026-01-01;18(1):2660482. doi:10.1080/20002297.2026.2660482 · PMID 42016708 · PMCID PMC13094239 · open access · cited by 1 (Europe PMC)
Additional documents
- Delta Dental of Michigan. Clinical criteria for periodontal scaling and root planing (v3, 2026) — signs required to justify D4341/D4342 (bleeding or exudate on probing, radiographic root calculus, mobility, furcation involvement, abscess), the ≥4-teeth-per-quadrant rule for D4341 and D4342 with the central tooth number (PDF)
- Connecticut Department of Social Services / DHP. Dental Coverage Limitations by Program (26 December 2024) — D4341 and D4342 covered for children under 21 regardless of medical condition; for adults 21+ only with treatable periodontal disease and at least one listed medical diagnosis evidenced in medical claims history; prior authorisation; D4910 twice per 12 months and not in conjunction with the SRP or exam codes (PDF)
- Connecticut DHP. Provider FAQs — New Limited Benefit: Periodontal Services for Qualifying Adults (26 December 2023, effective 1 January 2024) — prior authorisation required; published rates $223 per quadrant (D4341) and $129 per 1–3 teeth (D4342), rolling up to no more than four quadrants per 36-month period (PDF)
Bibliographic records above were retrieved and verified programmatically from Europe PMC (authors, journal, volume, pages, DOI, PMID, citation count). Coverage, guideline and regulatory statements are quoted from the cited public documents with their dates; verify against the current version before relying on them. This article is not medical or dental advice.